These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 10904462

  • 21. Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial.
    Tambascia MA, Geloneze B, Repetto EM, Geloneze SR, Picolo M, Magro DO.
    Diabetes Obes Metab; 2003 Sep; 5(5):338-44. PubMed ID: 12940872
    [Abstract] [Full Text] [Related]

  • 22. Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study.
    Hauner H, Meier M, Wendland G, Kurscheid T, Lauterbach K, Study Group SA, SAT Study.
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):201-7. PubMed ID: 15127325
    [Abstract] [Full Text] [Related]

  • 23. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder.
    Appolinario JC, Bacaltchuk J, Sichieri R, Claudino AM, Godoy-Matos A, Morgan C, Zanella MT, Coutinho W.
    Arch Gen Psychiatry; 2003 Nov; 60(11):1109-16. PubMed ID: 14609886
    [Abstract] [Full Text] [Related]

  • 24. Sibutramine produces dose-related weight loss.
    Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, Mendels J, Ryan DH, Schwartz SL, Scheinbaum ML, Seaton TB.
    Obes Res; 1999 Mar; 7(2):189-98. PubMed ID: 10102256
    [Abstract] [Full Text] [Related]

  • 25. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.
    Di Francesco V, Sacco T, Zamboni M, Bissoli L, Zoico E, Mazzali G, Minniti A, Salanitri T, Cancelli F, Bosello O.
    Ann Nutr Metab; 2007 Mar; 51(1):75-81. PubMed ID: 17356258
    [Abstract] [Full Text] [Related]

  • 26. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
    Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J.
    Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
    [Abstract] [Full Text] [Related]

  • 27. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial.
    Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL.
    JAMA; 2003 Apr 09; 289(14):1805-12. PubMed ID: 12684359
    [Abstract] [Full Text] [Related]

  • 28. Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
    Faria AN, Ribeiro Filho FF, Kohlmann NE, Gouvea Ferreira SR, Zanella MT.
    Diabetes Obes Metab; 2005 May 09; 7(3):246-53. PubMed ID: 15811141
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Treatment of binge eating disorder in racially and ethnically diverse obese patients in primary care: randomized placebo-controlled clinical trial of self-help and medication.
    Grilo CM, Masheb RM, White MA, Gueorguieva R, Barnes RD, Walsh BT, McKenzie KC, Genao I, Garcia R.
    Behav Res Ther; 2014 Jul 09; 58():1-9. PubMed ID: 24857821
    [Abstract] [Full Text] [Related]

  • 31. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
    Mathus-Vliegen EM, Balance Study Group.
    Eur J Clin Nutr; 2005 Aug 09; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
    [Abstract] [Full Text] [Related]

  • 32. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
    Gokcel A, Gumurdulu Y, Karakose H, Melek Ertorer E, Tanaci N, BascilTutuncu N, Guvener N.
    Diabetes Obes Metab; 2002 Jan 09; 4(1):49-55. PubMed ID: 11874442
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy.
    Serrano-Rios M, Melchionda N, Moreno-Carretero E, Spanish Investigators.
    Diabet Med; 2002 Feb 09; 19(2):119-24. PubMed ID: 11874427
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin.
    McNulty SJ, Ur E, Williams G, Multicenter Sibutramine Study Group.
    Diabetes Care; 2003 Jan 09; 26(1):125-31. PubMed ID: 12502668
    [Abstract] [Full Text] [Related]

  • 38. [Sibutramine in clinical practice - a PMS-study with positive effects on blood pressure and metabolic parameters].
    Scholze J.
    Dtsch Med Wochenschr; 2002 Mar 22; 127(12):606-10. PubMed ID: 11907862
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control.
    Gokcel A, Karakose H, Ertorer EM, Tanaci N, Tutuncu NB, Guvener N.
    Diabetes Care; 2001 Nov 22; 24(11):1957-60. PubMed ID: 11679464
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.